Results 11 to 20 of about 50,237 (216)

Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21. [PDF]

Adv Sci (Weinh)
EGFR mutations drive a substantial fraction of non‐small cell lung cancers (NSCLC) and are effectively targeted by tyrosine kinase inhibitors (TKIs), including osimertinib. However, resistance inevitably develops through secondary mutations and compensatory receptor activation, including the GAS6 receptor MERTK.
Giri S, Selvadurai BR, Gupta N, Simoni-Nieves A, Genna A, Lindzen M, Chatterjee R, Van Daele M, Ramesh Kumar D, Zerbib M, Oren R, Meijer IS, Wippich EF, Avraham Y, Dahan R, Haga Y, Kilpatrick LE, Platt S, Hill SJ, Pal LR, Ruppin E, Tsutsumi Y, Yardeni EH, Ahmad MA, Radinsky O, Romaniello D, Lauriola M, Porgador A, Yarden Y.   +28 more
europepmc   +2 more sources

Ras homolog family member A expression is associated with reduced cetuximab sensitivity in head and neck squamous cell carcinoma [PDF]

Journal of International Medical Research
Objectives Given that intrinsic and acquired resistance to cetuximab substantially limits its therapeutic efficacy in head and neck squamous cell carcinoma, we sought to elucidate the role of Ras homolog family member A in mediating cetuximab resistance ...
ChaoRong Bian, Xiaotong Zhao, Ping Shen, Runbang Wang, Di Pan, Wen Liu, Peng Zhou   +6 more
doaj   +2 more sources

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells

Toxins, 2023
Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affected by mCRC with KRAS mutation or in the presence of ...
Nicola Landi, Vincenza Ciaramella, Sara Ragucci, Angela Chambery, Fortunato Ciardiello, Paolo V. Pedone, Teresa Troiani, Antimo Di Maro   +7 more
doaj   +2 more sources

Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance

Neoplasia: An International Journal for Oncology Research, 2014
Overexpression of the epidermal growth factor receptor (EGFR) is observed in a large number of neoplasms. The monoclonal antibody cetuximab/Erbitux is frequently applied to treat EGFR-expressing tumors.
Agnieszka Weinandy, Marc D. Piroth, Anand Goswami, Kay Nolte, Bernd Sellhaus, Jose Gerardo-Nava, Michael Eble, Stefan Weinandy, Christian Cornelissen, Hans Clusmann, Bernhard Lüscher, Joachim Weis   +11 more
doaj   +2 more sources

Case Report about Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

Clinical Medicine Insights: Oncology, 2014
Hypersensitivity reactions are a classic side effect of cetuximab. We report the cases of three patients who developed life-threatening hypersensitivity to cetuximab, which could have been predicted by assessing the concentration of serum anticetuximab ...
Benoît Dupont, Delphine Mariotte, Cristian Moldovan, Jean-Michel Grellard, Marie-Claude Vergnaud, Dominique Laroche, Radj Gervais   +6 more
doaj   +2 more sources

New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer. [PDF]

Cancer Sci
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Takahashi M, Taniguchi SH, Yoshida Y.
europepmc   +2 more sources

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]

, 2012
Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Zielinski, Christoph C., Neumann, Jens, Stintzing, Sebastian, Ocvirk, Janja, Heinemann, Volker, Kurteva, Galina, Jung, Andreas, Modest, Dominik P., Brodowicz, Thomas, Knittelfelder, Regina, Kirchner, Thomas, Papai, Zsuzsanna, Laubender, Ruediger P.   +12 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. [PDF]

, 2020
Cetuximab, an IgG1 EGFR-directed antibody, promotes antibody-dependent cell-mediated cytotoxicity. We hypothesized that single-nucleotide polymorphisms (SNPs) in immune regulatory pathways may predict outcomes in patients with metastatic colorectal ...
Cremolini, Chiara, Alfredo Falcone, Stintzing, Sebastian, Zhang, Wu, Sebastian Stintzing, Cao, Shu, Yan Ning, Chiara Cremolini, Diana L. Hanna, Lenz, Heinz-Josef, Wu Zhang, Berger, Martin D., Heinz-Josef Lenz, Yang, Dongyun, Satoshi Matsusaka, Ning, Yan, Yu Sunakawa, Hanna, Diana L, Dongyun Yang, Shu Cao, Loupakis, Fotios, Nico B. Volz, Falcone, Alfredo, Martin D. Berger, Matsusaka, Satoshi, Sunakawa, Yu, Fotios Loupakis, Volz, Nico B, Berger M. D., Yang D., Sunakawa Y., Stintzing S., Ning Y., Cao S., Hanna D. L., Matsusaka S., Loupakis F., Lenz H. -J., Falcone A., Volz N. B., Cremolini C., Zhang W.   +41 more
core   +2 more sources

Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer

, 2021
Background: There are still few data on the activity and safety of cetuximab-based salvage chemotherapy after immunotherapy (SCAI) in patients with squamous cell cancer of the head and neck (SCCHN).
Cabrera Martín, María Nieves, Pérez Segura, Pedro, García-Barberán, Vanesa, Iglesias Moreno, María Cruz, Alonso-Ovies, Almudena, Cabezas-Camarero, Santiago, Paz-Cabezas, Mateo, Saiz-Pardo Sanz, Melchor, Merino Menéndez, Salome, María Nieves Cabrera-Martín, Melchor Sáiz-Pardo Sanz, Santiago Cabezas-Camarero, Maricruz Iglesias-Moreno, Mateo Paz-Cabezas, Vanesa García-Barberán, Salomé Merino-Menéndez, Almudena Alonso-Ovies, Pedro Pérez-Segura   +17 more
core   +1 more source